BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 9632068)

  • 1. Expression of costimulatory molecule CD80 on peripheral blood T cells in patients with systemic lupus erythematosus.
    Takasaki Y; Ogaki M; Abe K; Takeuchi K; Ando S; Tokano Y; Kobayashi S; Sekigawa I; Tsuda H; Hashimoto H
    J Rheumatol; 1998 Jun; 25(6):1085-91. PubMed ID: 9632068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and function of inducible costimulator on peripheral blood T cells in patients with systemic lupus erythematosus.
    Yang JH; Zhang J; Cai Q; Zhao DB; Wang J; Guo PE; Liu L; Han XH; Shen Q
    Rheumatology (Oxford); 2005 Oct; 44(10):1245-54. PubMed ID: 15987711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The quantitative analysis of peripheral blood FOXP3-expressing T cells in systemic lupus erythematosus and rheumatoid arthritis patients.
    Lin SC; Chen KH; Lin CH; Kuo CC; Ling QD; Chan CH
    Eur J Clin Invest; 2007 Dec; 37(12):987-96. PubMed ID: 18036033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced propensity of T lymphocytes in patients with systemic lupus erythematosus to apoptosis in the presence of tumour necrosis factor alpha.
    Habib HM; Taher TE; Isenberg DA; Mageed RA
    Scand J Rheumatol; 2009; 38(2):112-20. PubMed ID: 19110660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD134 expression on CD4+ T cells is associated with nephritis and disease activity in patients with systemic lupus erythematosus.
    Patschan S; Dolff S; Kribben A; Dürig J; Patschan D; Wilde B; Specker C; Philipp T; Witzke O
    Clin Exp Immunol; 2006 Aug; 145(2):235-42. PubMed ID: 16879242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression and clinical significance of inducible co-stimulator on peripheral blood T lymphocyte subsets in patients with systemic lupus erythematosus].
    Yang JH; Shen Q; Zhao DB; Cai Q; Han XH
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(5):318-23. PubMed ID: 15854508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of costimulatory molecules (CD80, CD86, CD28, CD152), accessory molecules (TCR alphabeta, TCR gammadelta) and T cell lineage molecules (CD4+, CD8+) in PBMC of leprosy patients using Mycobacterium leprae antigen (MLCWA) with murabutide and T cell peptide of Trat protein.
    Sridevi K; Neena K; Chitralekha KT; Arif AK; Tomar D; Rao DN
    Int Immunopharmacol; 2004 Jan; 4(1):1-14. PubMed ID: 14975355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus.
    Blanco P; Pitard V; Viallard JF; Taupin JL; Pellegrin JL; Moreau JF
    Arthritis Rheum; 2005 Jan; 52(1):201-11. PubMed ID: 15641052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus.
    Wong CK; Lit LC; Tam LS; Li EK; Lam CW
    Rheumatology (Oxford); 2005 Aug; 44(8):989-94. PubMed ID: 15870153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of CCR2 and CXCR3 in the T cell-mediated response occurring during lupus flares.
    Amoura Z; Combadiere C; Faure S; Parizot C; Miyara M; Raphaël D; Ghillani P; Debre P; Piette JC; Gorochov G
    Arthritis Rheum; 2003 Dec; 48(12):3487-96. PubMed ID: 14673999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expression of human leukocyte antigen-DR and CD25 on circulating T cells in cutaneous lupus erythematosus and correlation with disease activity.
    Wenzel J; Henze S; Brähler S; Bieber T; Tüting T
    Exp Dermatol; 2005 Jun; 14(6):454-9. PubMed ID: 15885081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The circulating lymphocyte profiles in patients with discoid lupus erythematosus and systemic lupus erythematosus suggest a pathogenetic relationship.
    Wouters CH; Diegenant C; Ceuppens JL; Degreef H; Stevens EA
    Br J Dermatol; 2004 Apr; 150(4):693-700. PubMed ID: 15099365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations of dendritic cells in systemic lupus erythematosus: phenotypic and functional deficiencies.
    Scheinecker C; Zwölfer B; Köller M; Männer G; Smolen JS
    Arthritis Rheum; 2001 Apr; 44(4):856-65. PubMed ID: 11315925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of Fcgamma and complement receptors on peripheral blood monocytes in systemic lupus erythematosus and rheumatoid arthritis.
    Hepburn AL; Mason JC; Davies KA
    Rheumatology (Oxford); 2004 May; 43(5):547-54. PubMed ID: 14747618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of increased CD4+CD25-Foxp3+ T cells in patients with new-onset systemic lupus erythematosus.
    Zhang B; Zhang X; Tang FL; Zhu LP; Liu Y; Lipsky PE
    Ann Rheum Dis; 2008 Jul; 67(7):1037-40. PubMed ID: 18199598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased CD161+CD8+ T cells in the peripheral blood of patients suffering from rheumatic diseases.
    Mitsuo A; Morimoto S; Nakiri Y; Suzuki J; Kaneko H; Tokano Y; Tsuda H; Takasaki Y; Hashimoto H
    Rheumatology (Oxford); 2006 Dec; 45(12):1477-84. PubMed ID: 16638798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormal telomerase activity and telomere length in T and B cells from patients with systemic lupus erythematosus.
    Kurosaka D; Yasuda J; Yoshida K; Yoneda A; Yasuda C; Kingetsu I; Toyokawa Y; Yokoyama T; Saito S; Yamada A
    J Rheumatol; 2006 Jun; 33(6):1102-7. PubMed ID: 16755657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The severity of systemic lupus erythematosus negatively correlates with the increasing number of CD4+CD25(high)FoxP3+ regulatory T cells during repeated plasmapheresis treatments of patients.
    Baráth S; Soltész P; Kiss E; Aleksza M; Zeher M; Szegedi G; Sipka S
    Autoimmunity; 2007 Nov; 40(7):521-8. PubMed ID: 17966042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral circulating activated b-cell populations are associated with nephritis and disease activity in patients with systemic lupus erythematosus.
    Dolff S; Wilde B; Patschan S; Dürig J; Specker C; Philipp T; Kribben A; Witzke O
    Scand J Immunol; 2007 Nov; 66(5):584-90. PubMed ID: 17868260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus.
    Bertsias GK; Nakou M; Choulaki C; Raptopoulou A; Papadimitraki E; Goulielmos G; Kritikos H; Sidiropoulos P; Tzardi M; Kardassis D; Mamalaki C; Boumpas DT
    Arthritis Rheum; 2009 Jan; 60(1):207-18. PubMed ID: 19116915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.